Who should receive myeloablative therapy for diffuse large B-cell lymphoma?

Nat Clin Pract Oncol. 2008 Aug;5(8):442-3. doi: 10.1038/ncponc1175. Epub 2008 Jul 8.

Authors

Luciano Wannesson¹, Emanuele Zucca

Affiliation

¹ Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

PMID: 18607392
DOI: 10.1038/ncponc1175

No abstract available

MeSH terms

Anthracyclines / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Disease Progression
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / surgery*
Myeloablative Agonists / therapeutic use*
Patient Selection
Rituximab
Transplantation, Autologous
Treatment Outcome

Substances

Anthracyclines
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Myeloablative Agonists
Rituximab